ALK and non-small cell lung carcinoma: The primary endpoint was also achieved in the intention-to-treat population that included stage IB, a subgroup that could benefit from adjuvant alectinib when also considering that ALK rearrangement in stage I NSCLC is significantly associated with poor prognosis compared to ALK-negative patients [26,27].